Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dustin R Donald
Observed names:
Dustin Donald,
Dustin R. Donald
Institutions:
National Organization for Rare Disorders,
Vanderbilt University Medical Center
Observed institutions:
Vanderbilt University,
National Organization for Rare Disorders,
Vanderbilt Health,
Vanderbilt University Medical Center
ORCID:
0000-0003-2646-341X
Observed ORCID:
0000-0003-2646-341X
OpenAlex ID:
A5061134873
Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model
2022
·
Dustin R. Donald
, Victoria W. Reynolds
, et al.
·
Journal of clinical lipidology
·
17
Institutional readiness for novel therapeutics: A framework for multidisciplinary integration
2025
·
Elizabeth G. Ames
, Nicholas A. Borja
, et al.
·
Molecular Genetics and Metabolism
·
1
PDF
Ultra-complex specialty medications: Meeting the challenges of significant medication requirements through an integrated specialty pharmacy model
2024
·
Chelsea P Renfro
, Dustin R Donald
, et al.
·
American Journal of Health-System Pharmacy
·
1
SUN-573 Use of PCSK9 Inhibitors Post-Transplant
2020
·
Juliana Matthews
, Dustin Donald
, et al.
·
Journal of the Endocrine Society
·
1
PDF
Optimizing maribavir management: The role of health system specialty pharmacies in access, monitoring, and waste reduction
2025
·
Dustin R. Donald
, Autumn D. Zuckerman
, et al.
·
Journal of Managed Care & Specialty Pharmacy
Show more works
View as search
Works count:
5
Citation count:
20
H-index:
1
I10-index:
1
Year
Topic
Type
